NYSE Arca · KAPA
Kairos Pharma, Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KAPA: Nov 13, 2026
Kairos Pharma, Ltd. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.63. The reported EPS for the same quarter last year was $-0.49.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Dec 2026 | $-0.77 | $-0.77 | $-0.77 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Oct 6, 10:04 AM EDTKairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial(RTTNews) – Kairos Pharma, Ltd. (KAPA), a clinical-stage biopharmaceutical company, announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer
- Fintel · Sep 15, 12:53 PM EDTKairos Pharma Consensus Price Target Increased by 600.00% to $49.98The average one-year price target for Kairos Pharma (NYSEAM:KAPA) has been revised to $49.98 / share. This is an increase of 600.00% from the prior estimate of $7.14 dated August 25, 2026. These figures represent aggregate analyst targets compiled as of September 11, 2026, and d
- RTTNews · Aug 24, 10:15 AM EDTKarios Pharma Hits 52-Week Low; Buzz Builds Around Reverse Split And Pipeline Milestone(RTTNews) – Kairos Pharma, Ltd. (KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance announced Friday that it will implement a 1-for-7 reverse stock split of its outstanding common shares.
- Zacks · Jul 2, 12:00 PM EDTAll You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to BuyKairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Jun 3, 9:10 AM EDTPre-Market Movers: PMI, CNTB, RNAZ Chart The Course(RTTNews) – Pre-market trading is offering an early glimpse into biotech stocks likely to attract investor attention this Wednesday.
- Fintel · Apr 14, 9:11 PM EDTKairos Pharma (KAPA) Price Target Decreased by 14.29% to 9.18The average one-year price target for Kairos Pharma (NYSEAM:KAPA) has been revised to $9.18 / share. This is a decrease of 14.29% from the prior estimate of $10.71 dated April 7, 2026. The price target is an average of many targets provided by analysts. The la
- Fintel · Apr 9, 2:02 AM EDTKairos Pharma (KAPA) Price Target Increased by 26.00% to 10.71The average one-year price target for Kairos Pharma (NYSEAM:KAPA) has been revised to $10.71 / share. This is an increase of 26.00% from the prior estimate of $8.50 dated March 25, 2026. The price target is an average of many targets provided by analysts. The
- RTTNews · Feb 27, 9:17 AM ESTWeekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX(RTTNews) – This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial s
- RTTNews · Feb 26, 8:53 PM ESTKairos Pharma Signs Term Sheet To Acquire Two Oncology Assets From Celyn Therapeutics; Stock Up(RTTNews) – Kairos Pharma Ltd. (KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, announced the signing of a term sheet to acquire two clinical oncology assets from privately held Celyn Therapeutics, Inc.
- Fintel · Nov 19, 1:43 PM ESTD. Boral Capital Maintains Kairos Pharma (KAPA) Buy RecommendationFintel reports that on November 19, 2025, D. Boral Capital maintained coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. Analyst Price Forecast Suggests 1,033.03% Upside
- RTTNews · Aug 27, 5:40 AM EDT5 Biotech Stocks To Watch Ahead Of Major Clinical Trial Data Readouts In September 2025(RTTNews) – September 2025 could be a make-or-break month for some biotech stocks, as the companies prepare to release critical clinical trial data.
- RTTNews · Jul 15, 10:39 AM EDTKairos Pharma Stock Soars After Positive Interim Results From Phase 2 Trial Of ENV-105(RTTNews) – Shares of Kairos Pharma, Ltd. (KAPA) are currently trading 88.2937 percent higher after announcing positive interim safety results from its ongoing Phase 2 trial of ENV-105 or Carotuximab in patients with metastatic castration-resistant prostate cancer known as mCRPC.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Kairos Pharma, Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.